Dekang Medical has been selected as the first company to participate in the FDA's Digital Health Device Pilot Program.
Golden Finance, July 23 — Continuous blood glucose monitoring device manufacturer Dexcom Medical has been selected by the U.S. FDA as the first company to participate in the TEMPO digital health device pilot project. The TEMPO project aims to evaluate new digital health technologies that help improve chronic disease management and provide real-world data. Dexcom Medical will implement an AI-driven blood glucose health program, combining data from Dexcom G7 and Stelo devices with contextual health information such as nutrition, physical activity, sleep, and stress, in order to provide more personalized insights for healthcare professionals and eligible users.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Selloff Sends Berkshire to Its Biggest S&P 500 Lead Since 2010: Can It Last?
Meridian weighs $400 million investment decision for Cabaçal mine
Saudi Arabia's oil production in October surged by 26%, reaching the highest level since the onset of the conflict, while Brent crude has dropped over 20% this month
OPEC's monthly report shows that Saudi Arabia's average daily crude oil production in October rose to 10.56 million barrels, just several hundred thousand barrels lower than the pre-war level in February and slightly above its quoted limit under the OPEC framework. Iraq's daily output in October also reached approximately 4.9 million barrels, a new high since the outbreak of war. Meanwhile, after the UAE exited OPEC and began competing in the market independently, both the UAE and Saudi Arabia recently slashed their official December cargo prices for Asian buyers, intensifying the competitive landscape.
Scorpio hits gold beyond Nevada resource
Crypto prices
More
